A Phase IIa single arm study to evaluate the safety and efficacy of YELIVA® in patient suffering from unresectable, intrahepatic and extrahepatic cholangiocarcinoma

Trial Profile

A Phase IIa single arm study to evaluate the safety and efficacy of YELIVA® in patient suffering from unresectable, intrahepatic and extrahepatic cholangiocarcinoma

Planning
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs ABC 294640 (Primary)
  • Indications Cholangiocarcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Apr 2017 New trial record
    • 04 Apr 2017 This trial is expected to initiate in the third quarter of 2017, as reported in a RedHill Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top